Private access

Jean Daniel LELIEVREJean-Daniel Lelièvre received his MD in Internal Medicine in 2002 (University Paris VII) and his PhD in immunology in 2002 (University Paris VII). He is professor in clinical immunology since 2010 and head the department of clinical immunology and infectious diseases of Henri Mondor’s hospital and the team 16 of INSERM U955.

His basic research was focused on T cell apoptosis during HIV infectio n during his PhD (under the supervision of Pr JC Ameisen) and moved after on the biology of Treg during HIV infection and basic aspects of T-cell development (role of Notch and IL7) and their disturbance during HIV infection.

Pr JD Lelièvre is currently the PI (or co-PI) of several clinical trials in the field of immune-based therapies of HIV or vaccinology (ANRS OPTIMAL role of treatment optimization with anti CCR5 in late diagnosis HIV + patients; ANRS LIGHT Therapeutic anti HIV vaccine, ANRS TREVE Kidney transplantation and raltegravir in HIV+ patients; ANRS VRI01, anti HIV prophylactic trial, EBOVAC2, anti Ebola vaccination).

He is in the charge of the clinical core of the VRI and of the WP 8 (prophylactic vaccine) of EHVA (European HIV Vaccine Alliance) a European consortium which encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. Pr Lelièvre JD is member of several committees of ANRS (CSS5, AC5, AC18) of the scientific and permanent committees of Sidaction, and of the program organizing committee of HIVR4P 2016.
Jean-Daniel Lelièvre is one of the leaders of the Clinical Development division of the VRI

Selected publications

[1] Kared H, Lelièvre JD, Donkova-Petrini V, Aouba A, Melica G, Balbo M, Weiss L, Lévy Y. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection AIDS 2008, 22:2451-60.
[2] Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM, Rouzioux C, Avettand V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M, Delfraissy JF. Repeated doses of rhIL7 improve T-cell recoveryin chronically HIV-1 infected adults. Results of a phase I/II Multicentre Study Journal of Clinical Investigation 2009; 119(4):997-1007.
[3] Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kök A, Huë S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Lévy Y. CD39/Adenosine pathway in HIV infection PLoS Pathogens 2011; 7 (7).
[4] Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD et al. Effects of rhIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients receiving antiretroviral therapy: results of a Phase I/IIa Randomized, Placebo Controlled, Multicenter Study. Clinical Infectious Diseases 2012; l;55(2):291-300.
[5] Jenabian M-A, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Ghadimi E, Kök A, Routy JP, Tremblay A, Sevigny J, Lelievre JD, Levy Y. Regulatory T Cells Negatively Affect IL-2 Production of Effector T Cells through CD39/Adenosine Pathway in HIV Infection. PLoS Pathogen 2013; 9(4): e1003319.
[6] Younas M, Hue S, Lacabaratz C, Guguin A, Wiedemann A, Surenaud M, Beq S, Croughs T, Lelièvre JD°, and Lévy Y°. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis Journal of Immunology 2013,15; 191(6):3161-8. (° co-last authors)
[7] Lahaye X, Satoh T, Cerboni S, Conrad C, Hurbain I, Marjou A, Lacabaratz C, Lelievre JD, Manel N. Cooperative cytosolic sensing of the HIV cDNA and capsid by dendritic cells elicits an adjuvant activity that stimulates innate and adaptive immunity without viral réplication Immunity, 2013; 39(6):1132-42.
[8] L Richert, A Doussau, JD Lelièvre, V Arnold, V Rieux, A Bouakane, Y Lévy, G Chêne and R Thiébaut. Accelerating clinical development of HIV vaccine stratégies methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design Trials 2014; 15:68.
[9] Carrière M, Lacabaratz C, Kök A, Benne C, Jenabian M, Casartelli N, Huë S, Hocqueloux L, Lelievre JD, and Levy Y. HIV “elite controllers” are characterized by a high frequency of memory CD8+CD73+ T-cells involved in the antigen-specific CD8+T-cell response accepté Journal of Infectious Diseases 2014; 209(9):1321-1330.
[10] Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Lévy Y, Lelièvre JD. P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART. PLoS Pathogens 2016; 12(4):e1005571.